Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS2 | Q07890 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21199960 | 0.84 | HSD11B1 (0.44) | SOS2HSD11B1CTSKCTSSPRMT5 | |
| SCHEMBL2962979 | 0.81 | KCNH2 (0.43) | SOS2HSD11B1CTSKCTSSAHR | |
| SCHEMBL378968 | 0.79 | CCR1 (0.40) | SOS2CCR1CTSKCTSSPRMT5 | |
| SCHEMBL3760158 | 0.79 | IRAK4 (0.49) | SOS2CTSKCTSSPRMT5WDR77 | |
| SCHEMBL31732088 | 0.79 | CCR1 (0.40) | HSD11B1CCR1NOTUM | |
| SCHEMBL14732983 | 0.79 | KCNH2 (0.44) | SOS2CTSKCTSS | |
| SCHEMBL947116 | 0.79 | CCR1 (0.40) | HSD11B1CCR1NOTUM | |
| SCHEMBL129485 | 0.79 | SOS2 (0.39) | SOS2CTSKCTSSPRMT5WDR77 | |
| SCHEMBL9297038 | 0.79 | SOS2 (0.39) | SOS2CTSKCTSSPRMT5WDR77 | |
| SCHEMBL29561378 | 0.79 | SOS2 (0.39) | SOS2CTSKCTSSPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118978522-A | Synthesis method of 2-substituted-4-hydroxy-2-thiazoline derivative | 信阳师范学院 | 2024-11-19 | — | — | CN | disclosed |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| EP-4122927-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022079432-A1 | 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2022-04-21 | — | — | WO | disclosed |
| US-20190224190-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-07-25 | — | — | US | disclosed |
| US-10307414-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| EP-3235814-B1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-12 | — | — | EP | disclosed |
| US-20180015083-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | TAKEDA CALIFORNIA, INC. | 2018-01-18 | — | — | US | disclosed |
| US-9801872-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-7666870-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2010-02-23 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090163477-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20090163477-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-7407957-B2 | e.g. 4-[5-(piperazine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent; septic shock; ischemic injury; reperfusion injury; hemorrhagic shock; and multiple sclerosis | MAYBRIDGE LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| US-7407957-B2 | e.g. 4-[5-(piperazine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent; septic shock; ischemic injury; reperfusion injury; hemorrhagic shock; and multiple sclerosis | MAYBRIDGE LIMITED (GB) | 2008-08-05 | — | — | US | disclosed |
| US-7129233-B2 | Mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2006-10-31 | — | — | US | disclosed |
| US-20040019033-A1 | Mandelic acid derivatives and their use as throbin inhibitors | ASTRAZENECA AB (SE) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163477-A1 | PHTHALAZINONE DERIVATIVES | PARP1, PARP2, PARP11 | SOS2 2756/4885HSD11B1 266/4885CCR1 1268/4885 |
| US-20040019033-A1 | Mandelic acid derivatives and their use as throbin inhibitors | ADAMTS1, ADAMTS13, ADAMTS7 | SOS2 4275/4885HSD11B1 461/4885CCR1 572/4885 |
| US-20180015083-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | SOS2 4268/4885HSD11B1 3857/4885CCR1 573/4885 |
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | SOS2 3051/4885HSD11B1 146/4885CCR1 726/4885 |
| US-20190224190-A1 | PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES | BTK, LCK, TYK2 | SOS2 4268/4885HSD11B1 3857/4885CCR1 573/4885 |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | ADORA2A, ADORA2B, ADORA3 | SOS2 1898/4885HSD11B1 1993/4885CCR1 1981/4885 |
| US-10307414-B2 | Pyridinyl and fused pyridinyl triazolone derivatives | BTK, LCK, TYK2 | SOS2 4268/4885HSD11B1 3857/4885CCR1 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.